Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Daniel B Costa

Showing results (101-110 of 175) with videos related to

Pageof 18
Sort By:
Lung Cancer (Amsterdam, Netherlands)|May 20, 2020
Safety and efficacy of immune checkpoint inhibitors in patients with non-small cell lung cancer and hepatitis B or hepatitis C infectionAna Pertejo-Fernandez, Biagio Ricciuti, Sarah P Hammond, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|March 12, 2016
Pulse Afatinib for ERBB2 Exon 20 Insertion-Mutated Lung AdenocarcinomasDaniel B Costa, Susan E Jorge, Jason P Moran, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|December 18, 2012
Compound EGFR mutations and response to EGFR tyrosine kinase inhibitorsSusumu Kobayashi, Hannah M Canepa, Alexandra S Bailey, et al.
European Journal of Haematology|February 17, 2006
A novel mutation in the last exon of ATRX in a patient with alpha-thalassemia myelodysplastic syndromeDaniel B Costa, Christopher A Fisher, Kenneth B Miller, et al.
Academic Radiology|March 4, 2017
Size Measurement and T-staging of Lung Adenocarcinomas Manifesting as Solid Nodules ≤30 mm on CT: Radiology-Pathology CorrelationBenedikt H Heidinger, Kevin R Anderson, Eoin M Moriarty, et al.
Plos Medicine|November 2, 2007
BIM mediates EGFR tyrosine kinase inhibitor-induced apoptosis in lung cancers with oncogenic EGFR mutationsDaniel B Costa, Balázs Halmos, Amit Kumar, et al.
Lung Cancer (Amsterdam, Netherlands)|January 22, 2016
Responses to the multitargeted MET/ALK/ROS1 inhibitor crizotinib and co-occurring mutations in lung adenocarcinomas with MET amplification or MET exon 14 skipping mutationSusan E Jorge, Sol Schulman, Jason A Freed, et al.
Journal of Thoracic Disease|January 21, 2012
Case series of treatment approaches in fit nonagenarians with stage IV non-small-cell lung cancerGregory J Britt, Elizabeth M Gaughan, Kim-Son H Nguyen, et al.
Cancers|March 28, 2024
A Real-World Study of Patient Characteristics and Clinical Outcomes in <i>EGFR</i> Mutated Lung Cancer Treated with First-Line Osimertinib: Expanding the FLAURA Trial Results into Routine Clinical PracticeHollis Viray, Andrew J Piper-Vallillo, Page Widick, et al.
Lung Cancer (Amsterdam, Netherlands)|November 9, 2013
Dual ALK and EGFR inhibition targets a mechanism of acquired resistance to the tyrosine kinase inhibitor crizotinib in ALK rearranged lung cancerNorihiro Yamaguchi, Antonio R Lucena-Araujo, Sohei Nakayama, et al.
Pageof 18

Showing results (101-110 of 175) with videos related to

Sort By:
Pageof 18
Lung Cancer (Amsterdam, Netherlands)|May 20, 2020
Safety and efficacy of immune checkpoint inhibitors in patients with non-small cell lung cancer and hepatitis B or hepatitis C infectionAna Pertejo-Fernandez, Biagio Ricciuti, Sarah P Hammond, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|March 12, 2016
Pulse Afatinib for ERBB2 Exon 20 Insertion-Mutated Lung AdenocarcinomasDaniel B Costa, Susan E Jorge, Jason P Moran, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|December 18, 2012
Compound EGFR mutations and response to EGFR tyrosine kinase inhibitorsSusumu Kobayashi, Hannah M Canepa, Alexandra S Bailey, et al.
European Journal of Haematology|February 17, 2006
A novel mutation in the last exon of ATRX in a patient with alpha-thalassemia myelodysplastic syndromeDaniel B Costa, Christopher A Fisher, Kenneth B Miller, et al.
Academic Radiology|March 4, 2017
Size Measurement and T-staging of Lung Adenocarcinomas Manifesting as Solid Nodules ≤30 mm on CT: Radiology-Pathology CorrelationBenedikt H Heidinger, Kevin R Anderson, Eoin M Moriarty, et al.
Plos Medicine|November 2, 2007
BIM mediates EGFR tyrosine kinase inhibitor-induced apoptosis in lung cancers with oncogenic EGFR mutationsDaniel B Costa, Balázs Halmos, Amit Kumar, et al.
Lung Cancer (Amsterdam, Netherlands)|January 22, 2016
Responses to the multitargeted MET/ALK/ROS1 inhibitor crizotinib and co-occurring mutations in lung adenocarcinomas with MET amplification or MET exon 14 skipping mutationSusan E Jorge, Sol Schulman, Jason A Freed, et al.
Journal of Thoracic Disease|January 21, 2012
Case series of treatment approaches in fit nonagenarians with stage IV non-small-cell lung cancerGregory J Britt, Elizabeth M Gaughan, Kim-Son H Nguyen, et al.
Cancers|March 28, 2024
A Real-World Study of Patient Characteristics and Clinical Outcomes in <i>EGFR</i> Mutated Lung Cancer Treated with First-Line Osimertinib: Expanding the FLAURA Trial Results into Routine Clinical PracticeHollis Viray, Andrew J Piper-Vallillo, Page Widick, et al.
Lung Cancer (Amsterdam, Netherlands)|November 9, 2013
Dual ALK and EGFR inhibition targets a mechanism of acquired resistance to the tyrosine kinase inhibitor crizotinib in ALK rearranged lung cancerNorihiro Yamaguchi, Antonio R Lucena-Araujo, Sohei Nakayama, et al.
Pageof 18